Abiraterone and Enzalutamide have different mechanisms of action and have their own advantages at present.
1、Progression Free Survival (PFS)
Abiraterone and Enzalutamide's PFS are similar.
Median (95% Confidence Interval)
Enzalutamide 5.7 (4.6 to 8.1)
Abiraterone 5.6 (4.5 to 7.3)
2、Side effect
EVIDENCE FROM AQUARiUS, a prospective observational multicenter phase IV study, showed that fewer patients with metastatic castration-resistant prostate cancer initiating therapy with abiraterone acetate plus prednisone experience worsening cognitive decline and worsening fatigue compared with enzalutamide over a 6-month period.1 Patients were assessed as to whether they had at least one episode of clinically meaningful worsening of cognitive function and fatigue.
This study enrolled 211 men taking either drug and followed them for 6 months using established instruments to measure patient-reported outcomes for cognition, fatigue, pain, and health-related quality of life. The study will continue for 12 months. Median age was 76 years; 12% had visceral metastases at baseline; and 15% were on opioids at baseline.
3、Which is best: Abiraterone or Enzalutamide?
In fact, from the point of view of current clinical medication, the efficacy of the two drugs is similar, and the side effects are more caused by individual differences of patients.
